Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
7 studies found for:    lymphoma OR CLL | Buparlisib
Show Display Options
Rank Status Study
1 Completed Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Conditions: Lymphoma;   Primary Central Nervous System Lymphoma;   Recurrent/Refractory Secondary Central Nervous System Lymphoma
Intervention: Drug: Buparlisib (BKM120)
2 Active, not recruiting Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Conditions: Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma
Interventions: Drug: Buparlisib;   Drug: Ibrutinib;   Biological: Ofatumumab
3 Recruiting A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Conditions: Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B Cell Lymphoma
Interventions: Drug: Buparlisib;   Drug: Ibrutinib
4 Active, not recruiting Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Buparlisib
5 Completed Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Drug: Buparlisib;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
6 Active, not recruiting Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
Condition: Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Intervention: Drug: BKM120
7 Recruiting Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: PI3K inhibitor BKM120;   Biological: rituximab;   Other: Pharmacodynamics;   Other: Correlative studies

Study has passed its completion date and status has not been verified in more than two years.